4-Aminopyrimidine-5-one derivatives

US7157455B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• David Joseph Bartkovitz · Nutley, US
• Xin-Jie Chu · Livingston, US
• Qingjie Ding · Bound Brook, US
• Nan Jiang · Fairfield, US
• Allen John Lovey · North Caldwell, US
• John Anthony Moliterni · Bloomfield, US
• John G. Mullin, Jr. · Hawthorne, US
• Binh Thanh Vu · North Caldwell, US
• Peter Michael Wovkulich · Nutley, US

Key dates

• Filing date: Feb 2, 2004
• Grant date: Jan 2, 2007
• Expiry date: Jan 12, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Novel 4-aminopyrimidine-5-one derivatives are disclosed. These compounds inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors. Also disclosed are intermediates useful in the preparation of these novel 4-aminopyrimidine-5-one derivatives.